| Disease Domain | Count |
|---|---|
| Neoplasms | 5 |
| Infectious Diseases | 3 |
| Nervous System Diseases | 2 |
| Endocrinology and Metabolic Disease | 1 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 12 |
Target |
Mechanism MAO-A inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MAO-A inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism VDR modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2026 |
Sponsor / Collaborator |
Start Date24 Nov 2025 |
Sponsor / Collaborator |
Start Date01 Sep 2025 |
Sponsor / Collaborator University of Oxford [+9] |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
BBIT20 ( BRCA1 ) | Ovarian Cancer More | Preclinical |
Kojic acid | Staphylococcus Aureus Infections More | Preclinical |
Maltol | Staphylococcus Aureus Infections More | Preclinical |
Compound 20(USC) ( MAO-A ) | Depressive Disorder More | Preclinical |
Compound 9(USC) ( MAO-A ) | Depressive Disorder More | Preclinical |






